Therini Bio raises funds to develop neurodegenerative disease therapies

2023-04-28

免疫疗法

Therini Bio raises funds to develop neurodegenerative disease therapies

Preview

来源: Pharmaceutical Technology

Therini Bio has raised $36m to develop fibrin-targeted therapies for the treatment of neurodegenerative and retinal diseases. Credit: MasterTux from Pixabay.

Biotechnology company Therini Bio has raised $36m in a Series A financing round to develop fibrin-targeted therapies to treat neurodegenerative and retinal diseases.

This brings the total amount raised by the company to date to $62m.

Recommended Reports

Preview

来源: Pharmaceutical Technology

ReportsInnovation in Pharmaceuticals: immunotherapy for neurodegenerative disease GlobalData

Preview

来源: Pharmaceutical Technology

ReportsLOA and PTSR Model - Drugs for Neurodegenerative Diseases GlobalData

View all

MRL Ventures Fund, Dementia Discovery Fund, Sanofi Ventures and SV Health Investors’ Impact Medicine Fund have co-led the financing round, which has also seen participation from existing investors including Dolby Family Ventures, the Foundation for a Better World and the Alzheimer’s Drug Discovery Foundation, along with new investor Eli Lilly and Company.

Therini Bio will use part of the funds to advance its potential first-in-class investigational antibody, THN391, into clinical trials.

THN391 binds the inflammation-driving component of fibrin, known for activating the immune responses in neurodegenerative and ophthalmologic diseases.

The company also plans to use the proceeds from the financing round to advance its fibrin-targeting therapies pipeline.

Therini Bio president and CEO Michael Quigley stated: “We are thrilled to announce a top-tier investor syndicate, which will allow us to advance our groundbreaking work in developing fibrin-targeted therapies for diseases driven by chronic inflammation.

“This funding will enable us to accelerate the development of our lead antibody programme targeting inflammatory fibrin in neurodegenerative and retinal diseases.

“We look forward to advancing our first candidate, THN391, into clinical trials, and expect to announce key safety and proof of mechanism clinical data by the end of 2024.”